Search - tctmd.com

Displaying 41 - 60 of 84

Sort: Relevancy | Date

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

L.A. McKeown

January 31, 2019

News Daily News

SYNTAX Score Should Not Guide Revascularization Strategy in FREEDOM-Like Patients

Michael O'Riordan

December 04, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

L.A. McKeown

December 11, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

Todd Neale

August 26, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

Advertisement

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

TCTMD’s Top 10 Most Popular Stories for October 2019

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

SYNTAX Score Should Not Guide Revascularization Strategy in FREEDOM-Like Patients

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

Statins and Diabetes: Causal Link Reinforced in New Analysis

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content